Navigation Links
Columbia research lifts major hurdle to gene therapy for cancer

Researchers at Columbia University Medical Center have discovered a way to overcome one of the major hurdles in gene therapy for cancer: its tendency to kill normal cells in the process of eradicating cancer cells. In a new study published in the Jan. 25 issue of the Proceedings of the National Academy of Sciences (PNAS), the researchers demonstrated that the technique works by incorporating it into a specially designed virus. The virus eradicated prostate cancer cells in the lab and in animals while leaving normal cells unscathed.

Gene therapy based on the new technique should also be effective for a wide range of tumors - such as ovarian, breast, brain (glioma), skin (melanoma) and colon cancer - because the virus is constructed to exploit a characteristic of all solid cancers. "What's exciting is we may now be able to design a therapy that will seek out and destroy only cancer cells," said the study's senior author, Paul B. Fisher, Ph.D., professor of clinical pathology and Michael and Stella Chernow Urological Cancer Research Scientist at Columbia University Medical Center. "We hope it will be particularly powerful in eradicating metastases that we can't see and that can't be eliminated by surgery or radiation. Gene therapy, especially for cancer, is really starting to make a comeback." The virus's selectivity for cancer cells is based on two molecules called PEA-3 and AP-1 that, the researchers found, are usually abundant inside cancer cells. Both of the molecules flip a switch (called PEG) that turns on the production of a cancer-inhibiting protein uniquely in tumor cells. The researchers say the PEG switch can be exploited to produce gene therapies that will only kill cancer cells even if the therapy enters normal cells. As an example, the researchers constructed an adenovirus that carries the PEG switch and a toxic protein. The switch and the protein were connected to each other so that the deadly protein is only unleashed inside cancer cells when the
'"/>

Source:Eurekalert


Page: 1 2

Related biology news :

1. Columbia study shows widely used artery clearing device does not help patients during heart attack
2. Columbia scientists develop cancer terminator viruses
3. Contaminants linked to sturgeon decline in Columbia river
4. Columbia University licenses next-generation DNA sequencing technology
5. New bird discovered on unexplored Columbian mountain
6. Columbia scientists determine 3-dimensional structure of cells fuel gauge
7. U of M researcher examines newly emerging deadly disease
8. NYU researchers simulate molecular biological clock
9. First atlas of key brain genes could speed research on cancer, neurological diseases
10. New research questions basic tenet of neuron function
11. Vital step in cellular migration described by UCSD medical researchers
Post Your Comments:
(Date:8/20/2008)...rk Capital Leads Round with Additional Funding by ...isting Investors Including Lockheed Martin, GE ... YORK, Aug. 20 /PRNewswire/ -- Clear(R), the fast ...on in venture funding. Led by new investor,Spark C... Syncom Venture,Partners, and existing investors L...
(Date:8/20/2008)...ugust 20, 2008) Today, the U.S. Environmental Prot...llion grant to the University of Kentucky (UK) to ...les affect their ability to enter the brain. This...AR) grant ever awarded to the University of Kentuc...d by EPA STAR for nanotechnology research. , "N...
(Date:8/20/2008)...EN tumor suppressor gene controls numerous biologi...rowth and death. But PTEN is frequently lost or mu...n among various types of human cancer that PTEN ha... tumor suppressors. , Now, a study led by resear...MC) and Harvard Medical School provides important...
(Date:8/20/2008)...an Genome Research Institute (NHGRI), part of the ... more than $20 million in grants to develop innova...ient enough to sequence a person,s DNA as a routin... "The ability to comprehensively sequence any per... usher in an age of personalized medicine where he...
Breaking Biology News(10 mins):Clear(R) Secures $44.4 Million in Venture Funding 2Clear(R) Secures $44.4 Million in Venture Funding 3$2M grant awarded to University of Kentucky for research on nanoparticles and human health 2New insights into the regulation of PTEN tumor suppression function 2NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 2NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 3NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 4NHGRI seeks DNA sequencing technologies fit for routine laboratory and medical use 5CHICOS and the American Heart Association Give this Holiday Season 6929 1Streamline Health Solutions Inc Reports Third Quarter Results 6927 1Streamline Health Solutions Inc Reports Third Quarter Results 6927 2Streamline Health Solutions Inc Reports Third Quarter Results 6927 3Streamline Health Solutions Inc Reports Third Quarter Results 6927 4Streamline Health Solutions Inc Reports Third Quarter Results 6927 5Streamline Health Solutions Inc Reports Third Quarter Results 6927 6Streamline Health Solutions Inc Reports Third Quarter Results 6927 7Streamline Health Solutions Inc Reports Third Quarter Results 6927 8Streamline Health Solutions Inc Reports Third Quarter Results 6927 9Streamline Health Solutions Inc Reports Third Quarter Results 6927 10Streamline Health Solutions Inc Reports Third Quarter Results 6927 11Streamline Health Solutions Inc Reports Third Quarter Results 6927 12Millennium Biotechnologies Inc Launches SURGEX 28TM 29 the First Scientifically Validated Sports Nutritional Product Created from the Medical Market 1952 1Millennium Biotechnologies Inc Launches SURGEX 28TM 29 the First Scientifically Validated Sports Nutritional Product Created from the Medical Market 1952 2Millennium Biotechnologies Inc Launches SURGEX 28TM 29 the First Scientifically Validated Sports Nutritional Product Created from the Medical Market 1952 3Millennium Biotechnologies Inc Launches SURGEX 28TM 29 the First Scientifically Validated Sports Nutritional Product Created from the Medical Market 1952 4Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference 1950 1Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference 1950 2Pharmacopeia To Present at BMO Capital Markets Seventh Annual Focus on Healthcare Conference 1950 3
... may reduce female fertility by directly affecting... the chances the embryo will implant, according to...in Europe,s leading reproductive medicine journal ... fertility experts in Portugal and Spain, comes as... non-heavy smokers and heavy smokers, all of whom ...
...ailed experiment turned out to be anything but for...zling out why what should have been a routine proc...to the creation of a new biological tool for destr...r to trigger antibiotic resistance. , The discov...technology firm that has already brought Wisconsin...
...y thought that animals can be arranged along a lad...urae—with humans inevitably at the top, followed b...own to fish and other slimy creatures. Over the pa...ms of high intelligence and great social complexit...tablish hierarchies in which dominant females supp...
...member this morning where I put my car keys last n...ntists at the Max Planck Institute for Medical Res...mories might be consolidated. Their new study offe...on is transferred between the hippocampus, the sho...g sleep. According to their findings and contrary ...
Other Biology News:Heavy smoking cuts women's chance of pregnancy -- even with donated oocytes 2Heavy smoking cuts women's chance of pregnancy -- even with donated oocytes 3'Failed' experiment yields a biocontrol agent that doesn't trigger antibiotic resistance 2'Failed' experiment yields a biocontrol agent that doesn't trigger antibiotic resistance 3Fishy cooperation 2Learning during sleep? 2
(Date:8/21/2008)... NEW YORK, MUNICH, Germany and AMSTERDAM, Neth...thcare and SpePharm Holding, B.V., the,pan-Europea...d that they,have entered into a euro 10 million re...fund SpePharm,s acquisition of Dantrium(R) for Eur...le Pharmaceuticals. At the same,time, TVM Capital,...
(Date:8/20/2008)... VIENNA, Va., Aug. 20 /PRNewswire-USNewswire/ ...0 ranking of the fastest-growing private companies...T) services provider,MicroTech, ranks No. 285 on ... 2008 Inc. 500 list measures revenue growth from 2...U.S.-based, privately held, independent -,no subsi...
(Date:8/20/2008)... INDIANAPOLIS, Ind., Aug. 20 /PRNewswire-First... announced that it has completed the acquisition,o...n Diego-based,biotechnology company focused on dru...y. The completion of the deal followed today,s Spe...SGX stockholders voted in,favor of the merger agre...
(Date:8/20/2008)... Growth Fueled by Popularity with Seniors and ... Marketing, CAMBRIDGE, Mass., Aug. 20 /PRNewswi...hole Health (SWH), a voluntary health care plan fo...ng private company in the,United States., Part of...rowing,companies, SWH had revenue growth of 31,000...
Breaking Biology Technology:TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 2TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 3TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 4TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm 5MicroTech Ranks No. 285 on Inc. Magazine's 2008 List of the 500 Fastest Growing Private Companies in America 2Lilly Announces Completion of SGX Acquisition 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 2Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US 3
...orp . will pay Third Wave Technologies $10.75 mi...t of their patent dispute, and they have agreed to...tration or licensing. , ,The case, which was litig...ct of Wisconsin in September 2005 and appealed to ...two companies that develop molecular diagnostic pr...
...ical , a Georgia-based maker of neural stem cell k... it can raise sufficient amounts of angel capital,...un out of the University of Georgia in Athens in...tate of Wisconsin and from Wisconsin Investment P..., but it will need more backing from angel investo...
... at the well-attended BICSI Conference . While I ...s data centers to get a first-hand view of its se...doing some online research, and I figured I would ...nd write another article because data centers ha...enters have become very important in the last coup...
...ing expenses offset strong quarterly revenue as S... media communications technology, reported a net l...irst quarter of fiscal year 2007. , ,The quarterl...n or 5 cents per share net loss in the same quarte...seasonally slow period, even though it reported re...
Other Biology Technology:Wisconsin tries to woo another stem cell company 2Wisconsin tries to woo another stem cell company 3Data centers: Blowing smoke and raising red flags 2Data centers: Blowing smoke and raising red flags 3Data centers: Blowing smoke and raising red flags 4Data centers: Blowing smoke and raising red flags 5Data centers: Blowing smoke and raising red flags 6
DUALmembrane starter package from Dualsystems Biotech AG
Human/Mouse/Rat p38 alpha Affinity Purified PAb
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins.
Biology Products: